🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

Recruitingn/aAges 18 Years - 50 YearsFemaleOhio State University
NCT06184373 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Women with a viable singleton intrauterine pregnancy * Able to understand the study, and having understood, provide written informed consent in English * Recent pregnancy affected by gestational diabetes Exclusion Criteria: * Pregestational Diabetes (Type I or Type II) * Continued use of diabetes medications (including metformin and insulin) immediately after delivery * Preterm delivery (\< 37 weeks gestation) * Twin or higher order gestation * No access to a smartphone * Unable or unwilling to wear CGM or return for follow up at postpartum mother-infant dyad clinic * Participation in this trial in a prior pregnancy * History of skin allergy to adhesive products or CGM
💊

What it tests

  • Continuous glucose monitor
  • Oral Glucose Tolerance Test
  • Hemoglobin A1c
📍

Where

1 site
Ohio State University Medical Center
Columbus, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy